Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation

Yuriko Ishida, Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Takashi Ogura
ERJ Open Research 2022 8: 00337-2022; DOI: 10.1183/23120541.00337-2022
Yuriko Ishida
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Ikeda
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Satoshi Ikeda
  • For correspondence: isatoshi0112@gmail.com
Akimasa Sekine
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomohisa Baba
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Ogura
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

This article is a correspondence to the review article on lung cancer with comorbid interstitial pneumonia, particularly with regard to pharmacotherapy. Limited evidence needs to be accurately evaluated and utilised for these patients with poor prognosis. https://bit.ly/3BGRCz4

To the Editor:

We have read with interest the article entitled “Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges” by Kewalramani et al. [1]. ∼10% of lung cancer patients are complicated with interstitial pneumonia and have a poor prognosis. Although there is a lack of evidence in this area, the article clearly summarises the current status from epidemiology to treatment, and is very informative for clinicians. However, there were three points that could be misleading to the reader, especially in the description of pharmacotherapy.

First, the authors stated that as second-line therapy for lung cancer patients with fibrosing interstitial pneumonia, vinorelbine should be administered for squamous cell carcinoma and pemetrexed for adenocarcinoma. However, a Japanese nationwide survey on pharmacotherapy for lung cancer patients with interstitial pneumonia reported that acute exacerbations of pre-existing interstitial pneumonia occurred in 28.6% of patients treated with pemetrexed and 25% of patients treated with vinorelbine [2]. Conversely, docetaxel, which was not recommended by the authors, had a lower incidence of acute exacerbations (15.3%). Together with several past reports on the safety of paclitaxel and nab-paclitaxel in lung cancer patients with interstitial pneumonia, the taxanes may have a relatively low risk of acute exacerbations. In addition, S-1, which had the lowest incidence of acute exacerbations in an aforementioned report by Minegishi et al. [2], is often administered as second-line therapy for lung cancer patients with interstitial pneumonia in Japanese clinical practice.

Second, the authors stated that reports of immune checkpoint inhibitors (ICIs) are scarce, with only retrospective cohort studies and limited numbers of patients. While no prospective studies have been reported to date investigating ICIs as first-line treatment for advanced lung cancer patients with interstitial pneumonia, all three previously reported prospective trials of second-line or later therapy were on ICI monotherapy for advanced non-small cell lung cancer (NSCLC) with interstitial pneumonia, and none were on cytotoxic chemotherapy [3–5]. These three studies of ICI differed in their selection criteria for interstitial pneumonia and in the incidence of ICI-induced pneumonitis, which ranged from 0% to 30%. At present, the safety of ICIs in patients with interstitial pneumonia has not been adequately established, and the pros and cons of administration remain controversial. However, retrospective studies on cytotoxic agents (e.g. docetaxel and pemetrexed) as second-line or later therapy in NSCLC patients with comorbid interstitial pneumonia showed a 1-year survival of, at most, 10%, which is far from promising for long-term survival [6, 7]. Conversely, phase II trials of ICIs for NSCLC patients with interstitial pneumonia have consistently shown favourable efficacy; a nivolumab trial had a median overall survival of 15.6 months, while an atezolizumab trial had a 1-year survival rate of 53.3% [4, 8]. Since ICIs are the only treatment option that can provide long-term survival in poor-prognosis lung cancer patients with interstitial pneumonia, an important clinical issue is how to “narrow down” interstitial pneumonias with low risk of ICI-induced pneumonitis.

Third, there were some inaccuracies in the authors' description of the J-SONIC trial, the world's first randomised phase III trial in NSCLC with idiopathic pulmonary fibrosis (IPF). The authors stated that the addition of nintedanib to carboplatin plus nab-paclitaxel prolonged the interval to acute exacerbation, but in fact, the primary endpoint of exacerbation-free survival (defined as the time from randomisation to the date of acute exacerbation of IPF or death from any cause) and the secondary endpoint of time to acute exacerbation of IPF were not met, indicating that the addition of nintedanib was not effective in reducing acute exacerbations [9]. The incidence of acute exacerbations was low throughout the trial due to the high safety of carboplatin plus nab-paclitaxel itself and the relatively preserved lung function of the enrolled patients. This may have made it difficult to prove the efficacy of nintedanib in preventing acute exacerbations. However, a subgroup analysis of non-squamous NSCLC patients showed significant prolongations in both progression-free survival and overall survival, indicating enhanced anti-tumour effect with nintedanib. Therefore, the addition of nintedanib would be one of the treatment options for non-squamous NSCLC patients with IPF.

When an article is published in a high-impact journal like yours, it is highly likely that readers will take the content of the article as it is and reflect it in their clinical practice. For this reason, we are submitting this correspondence article. Meanwhile, we believe that it is very significant that such an excellent review article has been published by European opinion leaders. We hope that this will lead to the generation of further evidence from around the world, and the planning of international collaborative studies involving countries in Europe and Asia in the future.

Acknowledgements

We would like to express our sincere gratitude to Yukiko Ogasawara, Yuka Onoda, Noriko Kanda and Kiriko Sato (Clinical Research Center, Kanagawa Cardiovascular and Respiratory Center, Japan) for their efforts in data collection.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Author contributions: Y. Ishida: formal analysis, investigation and writing (original draft). S. Ikeda: formal analysis, investigation and writing (original draft). T. Baba: investigation and writing (review and editing). A. Sekine: investigation and writing (review and editing). T. Ogura: investigation and writing (review and editing).

  • Conflicts of interest: A. Sekine has received honoraria for lectures from AstraZeneca, Ono, Eli Lily and Boehringer Ingelheim, outside the submitted work.

  • Conflicts of interest: S. Ikeda has received research funds from Chugai Pharmaceutical Co, Ltd. and AstraZeneca K.K., outside the submitted work; and honoraria for lectures from Chugai Pharmaceutical Co, Ltd., Ono Pharmaceutical Co, Ltd., Boehringer Ingelheim, Eli Lilly K.K, Bristol-Myers Squibb, AstraZeneca K.K., Pfizer and Taiho Pharma, outside the submitted work.

  • Conflicts of interest: T. Baba has received honoraria for lectures from AstraZeneca, Daiichi-Sankyo and Boehringer Ingelheim, outside the submitted work.

  • Conflicts of interest: T. Ogura has received honoraria for lectures from Shionogi, Eisai and Boehringer Ingelheim, outside the submitted work.

  • Conflicts of interest: Y. Ishida has nothing to disclose.

  • Received July 7, 2022.
  • Accepted July 28, 2022.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Kewalramani N,
    2. Machahua C,
    3. Poletti V, et al.
    Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges. ERJ Open Res 2022; 8: 00115-2022. doi:10.1183/23120541.00115-2022
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Minegishi Y,
    2. Gemma A,
    3. Homma S, et al.
    Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. ERJ Open Res 2020; 6: 00184-2019. doi:10.1183/23120541.00184-2019
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Fujimoto D,
    2. Morimoto T,
    3. Ito J, et al.
    A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer 2017; 111: 1–5. doi:10.1016/j.lungcan.2017.06.008
    OpenUrlPubMed
  4. ↵
    1. Fujimoto D,
    2. Yomota M,
    3. Sekine A, et al.
    Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: a multicenter, open-label single-arm phase II trial. Lung Cancer 2019; 134: 274–278. doi:10.1016/j.lungcan.2019.06.001
    OpenUrl
  5. ↵
    1. Ikeda S,
    2. Kato T,
    3. Kenmotsu H, et al.
    A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis. J Thorac Oncol 2020; 15: 1935–1942. doi:10.1016/j.jtho.2020.08.018
    OpenUrlCrossRef
  6. ↵
    1. Watanabe N,
    2. Niho S,
    3. Kirita K, et al.
    Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother Pharmacol 2015; 76: 69–74. doi:10.1007/s00280-015-2775-y
    OpenUrl
  7. ↵
    1. Kato M,
    2. Shukuya T,
    3. Takahashi F, et al.
    Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer 2014; 14: 508. doi:10.1186/1471-2407-14-508
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ikeda S,
    2. Kato T,
    3. Kenmotsu H, et al.
    Atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonia: final analysis of phase II AMBITIOUS study. Oncologist 2022; 27: 720–e702.
    OpenUrl
  9. ↵
    1. Otsubo K,
    2. Kishimoto J,
    3. Ando M, et al.
    Nintedanib plus chemotherapy for non-small cell lung cancer with IPF: a randomized phase 3 trial. Eur Respir J 2022; in press [https://doi.org/10.1183/13993003.00380-2022].
PreviousNext
Back to top
Vol 8 Issue 4 Table of Contents
ERJ Open Research: 8 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
Yuriko Ishida, Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Takashi Ogura
ERJ Open Research Oct 2022, 8 (4) 00337-2022; DOI: 10.1183/23120541.00337-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
Yuriko Ishida, Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Takashi Ogura
ERJ Open Research Oct 2022, 8 (4) 00337-2022; DOI: 10.1183/23120541.00337-2022
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgements
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Lung cancer
  • Pulmonary pharmacology and therapeutics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • It is time to end our love affair with SABA in asthma?
  • Nanopore-based metagenomic sequencing
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society